India Targets US$130 Billion Pharma Market and US$80 Billion in Exports by 2030, ASSOCHAM Projects

India's pharmaceutical sector is on a trajectory that will reshape global contract manufacturing pipelines and biosimilar supply chains well before the decade closes, according to a knowledge paper released by ASSOCHAM projecting a US$130 billion domestic market and US$80 billion in exports by 2030.

The ASSOCHAM paper identifies four structural drivers behind the expansion: biosimilars and biologics development, AI-driven drug discovery, contract manufacturing scale-up, and regulatory harmonization with major reference agencies. For QA directors and regulatory affairs leads at multinational manufacturers sourcing from Indian CDMOs, the harmonization agenda carries the most immediate operational weight, alignment with ICH Q10 principles and convergence toward 21 CFR Part 211 equivalency standards will determine which Indian facilities remain audit-ready for US and EU supply chains.

The biosimilar and biologics segment is positioned as the primary export growth engine. India's existing generics infrastructure provides a manufacturing base, but the biologics scale-up demands a step-change in sterility assurance protocols, cold-chain validation, and process validation documentation, areas where Indian manufacturers have faced repeat observations during US FDA and EMA inspections in recent cycles.

Contract manufacturing is the second lever. As multinational originators continue to rationalize internal manufacturing networks, Indian CDMOs are absorbing a larger share of fill-finish and API production. Plant heads evaluating new CDMO partnerships will need to weigh not only cost and capacity, but the depth of quality management systems and the facility's inspection history against the projected volume commitments the ASSOCHAM forecast implies.

AI-driven drug discovery, while earlier in its operational maturity, signals a longer-term shift in where India positions itself in the pharmaceutical value chain, moving from volume-based generics manufacturing toward molecule origination and development services. The near-term compliance and supply-chain implications are limited, but the trajectory is relevant for strategic sourcing decisions being made now with five-to-seven-year horizons.

The 2030 targets will be tested against India's ability to sustain GMP compliance at scale, reduce import alert exposure, and accelerate post-approval change management under evolving ICH guidance, measurable checkpoints that will determine whether the US$80 billion export figure is achievable or aspirational.

Source: ASSOCHAM knowledge paper via Media4Growth / Indian Pharma Post, 11 June 2026.